Leader Biomedical Introduces Spine Portfolio with Targeted Therapeutic Solutions
Amsterdam, Netherlands, July 20, 2018 --(PR.com)-- Leader Biomedical introduces new Spine Portfolio with the launch of three targeted therapeutic solutions Adcon® Gel, Hyalosyn™ Gel, and Vebroplast® addressing adhesions, joint mobility, and vertebral compression fractures, respectively.
Adcon® Gel is a biocompatible resorbable gel that provides a barrier to inter-tissue adhesions and inhibits fibroblast migration. The result is improved patient rehabilitation, reduced recurrent pain, and decreased number re-operations as a result of such adhesions. Adcon® Gel has been used and proven in over 300,000 cases and in more than 10 clinical studies since 1996.
Hyalosyn™ Gel is a sodium hyaluronate viscoelastic solution in a syringe for long-term effect on improved joint mobility, suitable for intra-articular injection into all synovial joints. Hyalosyn™ Gel is manufactured by unique biotechnological synthetic fermentation, ensuring a high purity with no microbiological residues. Hyalosyn™ Gel has an extensive clinical history of more than 10 years with proven pain relief and treatment of degenerative joints.
Vebroplast® is biocompatible acrylic (PMMA) spine cement used for the strengthening, fixation, and filling vertebrae after a vertebral compression fracture (VCF) through a quick and relatively safe intervention. Vebroplast® further contains barium sulphate used to improve visualisation under fluoroscopy and its composition ensures biomechanical strength and firmness maintaining penetrative and fixing properties while injecting it under low pressure.
Leader Biomedical’s Spine Portfolio is completed with eTiss® allografts processed and cleaned with our proprietary eCOO® Technology utilising super critical carbon dioxide (scCO2) and the OssGro® and Ossfinity® line of synthetic grafts produced with MBCP™ Technology, a proprietary method composed of 60% HA and 40% βTCP. To further augment the Spine offering, Leader Biomedical will shortly introduce mixing and delivery systems for vertebroplasty and kyphoplasty.
The introduction of the Spine Portfolio adds to Leader Biomedical’s existing therapeutic portfolios of targeted solutions for Dental, Joint Care and Sports Medicine. This further supports the company’s commitment to contribute to the betterment of the global healthcare community thus extending the reach of patients and caregivers by improving global access to reliable, targeted therapeutic solutions and new technologies.
Media Contact:
Sandy Plat
Group Marketing & Communication Manager
media@leaderbiomedical.com | +31 (0)6 2972 6530 | https://www.linkedin.com/in/sandyplat/
About Leader Biomedical:
Leader Biomedical is committed to improving access to innovative biomaterials and implantable medical devices, thereby extending the reach of patients and caregivers worldwide. We contribute to the betterment of the healthcare sector by developing new technologies, delivering world-class contract manufacturing, and providing targeted therapeutic solutions for dental, spine, joint care, and sports medicine indications (www.leaderbiomedical.com).
Adcon® Gel is a biocompatible resorbable gel that provides a barrier to inter-tissue adhesions and inhibits fibroblast migration. The result is improved patient rehabilitation, reduced recurrent pain, and decreased number re-operations as a result of such adhesions. Adcon® Gel has been used and proven in over 300,000 cases and in more than 10 clinical studies since 1996.
Hyalosyn™ Gel is a sodium hyaluronate viscoelastic solution in a syringe for long-term effect on improved joint mobility, suitable for intra-articular injection into all synovial joints. Hyalosyn™ Gel is manufactured by unique biotechnological synthetic fermentation, ensuring a high purity with no microbiological residues. Hyalosyn™ Gel has an extensive clinical history of more than 10 years with proven pain relief and treatment of degenerative joints.
Vebroplast® is biocompatible acrylic (PMMA) spine cement used for the strengthening, fixation, and filling vertebrae after a vertebral compression fracture (VCF) through a quick and relatively safe intervention. Vebroplast® further contains barium sulphate used to improve visualisation under fluoroscopy and its composition ensures biomechanical strength and firmness maintaining penetrative and fixing properties while injecting it under low pressure.
Leader Biomedical’s Spine Portfolio is completed with eTiss® allografts processed and cleaned with our proprietary eCOO® Technology utilising super critical carbon dioxide (scCO2) and the OssGro® and Ossfinity® line of synthetic grafts produced with MBCP™ Technology, a proprietary method composed of 60% HA and 40% βTCP. To further augment the Spine offering, Leader Biomedical will shortly introduce mixing and delivery systems for vertebroplasty and kyphoplasty.
The introduction of the Spine Portfolio adds to Leader Biomedical’s existing therapeutic portfolios of targeted solutions for Dental, Joint Care and Sports Medicine. This further supports the company’s commitment to contribute to the betterment of the global healthcare community thus extending the reach of patients and caregivers by improving global access to reliable, targeted therapeutic solutions and new technologies.
Media Contact:
Sandy Plat
Group Marketing & Communication Manager
media@leaderbiomedical.com | +31 (0)6 2972 6530 | https://www.linkedin.com/in/sandyplat/
About Leader Biomedical:
Leader Biomedical is committed to improving access to innovative biomaterials and implantable medical devices, thereby extending the reach of patients and caregivers worldwide. We contribute to the betterment of the healthcare sector by developing new technologies, delivering world-class contract manufacturing, and providing targeted therapeutic solutions for dental, spine, joint care, and sports medicine indications (www.leaderbiomedical.com).
Contact
Leader Biomedical
Sandy Plat
+31 (0)6 2972 6530
Sandy Plat
+31 (0)6 2972 6530
Contact
Categories